

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:)	BOX PCT
)	
John C. ALEXANDER, et al.)	National Phase Application
)	PCT/US00/05633
Serial No. Unassigned)	Filed: March 3, 2000
)	
Filed: Concurrently Herewith)	Group Art Unit: Unassigned
)	
For: COMBINATION THERAPY OF)	Examiner: Unassigned
ANGIOTENSIN CONVERTING ENZYME)	
INHIBITOR AND EPOXY-STEROIDAL)	
ALDOSTERONE ANTAGONIST FOR)	
TREATMENT OF CARDIOVASCULAR)	
DISEASE)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted for consideration by the United States Patent and Trademark Office in accordance with the duty of disclosure.

Transmitted herewith is:

- ☒ [X] A PTO 1449 form
- ☐ [] A Background Art Information Paper
- ☒ [X] A copy of each item of information listed on the PTO 1449 form
- ☐ [] Concise explanation of non-English language information
- ☒ [X] concise explanation of relevance:
- ☐ [] English translation of foreign language information

☒ English language version of foreign patent office report citing information

☐ English language abstract(s) of foreign patent document(s)

☐ This application relies, under 35 U.S.C. §120, on the earlier filing date of U.S. Application Serial No. ****, filed ***. The information identified on the attached PTO 1449 form was submitted to and/or cited by the Patent and Trademark Office in this earlier application and, therefore, copies are not required to be provided in this application.

1. ☒ This Information Disclosure Statement is filed before the later of:
- ☐ three months from the filing date of this national application;
 - ☒ three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or
 - ☐ the mailing date of a first office action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

2. ☐ This Information Disclosure Statement is filed after the events noted in paragraph 1, but before either:
- ☐ a final action under 37 CFR 1.113, or an action that otherwise closes prosecution,
 - ☐ a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(c), also enclosed is

- ☐ a fee under 37 CFR 1.17(p) for \$180.00; or
 - ☐ a certification as stated below.
3. ☐ This Information Disclosure Statement is filed before payment of the issue fee, but after either
- ☐ a final action under 37 CFR 1.113, or an action that otherwise closes prosecution;

☐ a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(d), also enclosed is:

☐ a certification, as stated below; and

☐ the IDS processing fee set forth in 37 CFR 1.17(p)(1) in the amount of \$180.00.

Certification

The undersigned states:

☐ Each item of Information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

TOTAL FEES: \$

☐ A check for the amount of the above indicated TOTAL FEES is attached.

☐ Please charge Deposit Account No. 19-0733 in the amount of \$.

☐ A check for \$ is enclosed.

☒ No fee is required.

☐ Please charge or credit Deposit Account No. 19-0733 for an deficiency or overpayment associated with this Information Disclosure Statement.

A duplicate copy of this sheet is enclosed for accounting purposes.

It is respectfully requested that the Examiner fully consider each item of information, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the information has

Attorney Docket No. 61765.00334

been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By: Ajay Pathak
Ajay Pathak
Registration No. 38,266

Eleventh Floor
1001 G Street, N.W.
Washington, D.C. 20001-4597
(202) 508-9100

Dated: September 5, 2001

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION Sheet 1 of 1				Attorney Docket No. 61765.00334		International Serial No. PCT/US00/05633	
				Applicant(s): John C. ALEXANDER, et al.			
				International Filing Date: March 3, 2000		Group: Unassigned	

U.S. PATENT DOCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS							
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
	96/40257	12/19/96	WIPO				
	96/40255	12/19/96	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)	
	W.J. REMME: "Modulation of the renin-angiotensin-aldosterone system-pivotal in heart failure treatment" ZEITSCHRIFT FUR KARDIOLOGIE, vol. 88, no. 3, 1999, pp. 12-17, XP002136875
	P. BITT, B. RONIKER: "Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose finding study in patients with heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 33, no. 2/A, 1999, page 1188A, XP002136876

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.